Document is current
Any future updates will be listed below
-
Authors
Barnett-Tapia, Carolina https://orcid.org/0000-0001-5546-0221
Cortés Vicente, Elena
Pascuzzi, Robert M.
Utsugisawa, Kimiaki
Bloemers, Jos
Grimson, Fiona
Tarancón, Thaïs
Bril, Vera
,
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03971422 at ClinicalTrials.govDocuments that mention this clinical trial
Measuring the effect of rozanolixizumab using the Myasthenia Gravis Impairment Index: analyses from the randomized phase 3 MycarinG study
https://doi.org/10.1007/s00415-025-13480-8
Response to rozanolixizumab across treatment cycles in patients with generalised myasthenia gravis: post hoc analysis
https://doi.org/10.1136/jnnp-2024-abn.167
2999 Response to rozanolixizumab across treatment cycles in patients with generalised myasthenia gravis: a <i>post hoc</i> analysis
https://doi.org/10.1136/bmjno-2024-anzan.36
1 Rozanolixizumab treatment patterns in patients with generalised myasthenia gravis: post hoc analysis
https://doi.org/10.1136/jnnp-2025-abn.1
Rozanolixizumab efficacy in generalised myasthenia gravis: Subgroup analyses from the randomised, phase 3, MycarinG study
https://doi.org/10.1136/jnnp-2023-abn.253
3595 Effect of rozanolixizumab on ocular symptoms in generalised myasthenia gravis: <i>post hoc</i> item-level analysis of myasthenia gravis-specific outcomes in MycarinG
https://doi.org/10.1136/bmjno-2025-anzan.138
-
Funding
Funding for this research was provided by:
UCB Pharma
- License Information
-
More Information
Article History
Received: 22 July 2025
Revised: 15 October 2025
Accepted: 17 October 2025
First Online: 8 November 2025
Declarations
:
: Carolina Barnett-Tapia has served as a paid Consultant for Alexion Pharmaceuticals, argenx, Janssen Pharmaceuticals (now Johnson & Johnson Innovative Medicine), Novartis and UCB. She has received research support from MGNet, Muscular Dystrophy Canada and the US Department of Defense. She is the primary developer of the MGII and may receive royalties for its use. Elena Cortés Vicente receives public speaking honoraria and compensation for advisory boards and/or consultation fees from Alexion Pharmaceuticals, argenx, Janssen Pharmaceuticals (now Johnson & Johnson Innovative Medicine) and UCB. Robert M. Pascuzzi is Professor Emeritus of Neurology at Indiana University and receives compensation for his professional work from Indiana University Health. He has no financial relationship with any pharmaceutical company and receives no compensation from any pharmaceutical company (present or past). Robert M. Pascuzzi speaks at educational seminars on a broad variety of general neurology topics for primary care physicians through the organization Medical Education Resources (an educational organization with no links or ties to any pharmaceutical or healthcare business company). Therefore, Robert M. Pascuzzi has no conflicts of interest related to this research, manuscript, presentation, or publication. Kimiaki Utsugisawa has served as a paid Consultant for argenx, Chugai Pharmaceutical, HanAll Biopharma, Janssen Pharmaceuticals (now Johnson & Johnson Innovative Medicine), Merck, Mitsubishi Tanabe Pharma, UCB and Viela Bio (now Amgen); he has received speaker honoraria from Alexion Pharmaceuticals, argenx, the Japan Blood Products Organization and UCB. Jos Bloemers is an employee and shareholder of UCB. Fiona Grimson is an employee and shareholder of UCB. Thaïs Tarancón is an employee and shareholder of UCB. Vera Bril is a Consultant for Akcea, Alexion Pharmaceuticals, Alnylam, argenx, CSL, Grifols, Immunovant, Ionis, Janssen Pharmaceuticals (now Johnson & Johnson Innovative Medicine), Momenta (now Johnson & Johnson), Novo Nordisk, Octapharma, Pfizer, Powell Mansfield, Roche, Sanofi, Takeda Pharmaceuticals and UCB. She has received research support from Akcea, Alexion Pharmaceuticals, argenx, CSL, Grifols, Immunovant, Ionis, Momenta (now Johnson & Johnson), Octapharma, Takeda Pharmaceuticals, UCB and Viela Bio (now Amgen).
: This study was performed in accordance with the principles of the Declaration of Helsinki. A national, regional or independent ethics committee or institutional review board (depending on site) approved the protocol. All patients provided written informed consent.
